


## Shilpa Medicare launches new full-service hybrid CDMO

11 March 2025 | News

## Integrated CDMO has capabilities spanning small and large molecules as well as peptides



Raichur-based Shilpa Medicare has launched its new full service 'hybrid' contract development and manufacturing organisation (CDMO). The newly formed CDMO will see Shilpa serve both small and large molecules customers as well as peptides – with oncology a particular therapeutic specialism.

In addition to offering comprehensive discovery, clinical, and commercial outsourcing services, Shilpa's 'hybrid CDMO model' also includes commercially ready 'off-the-shelf' novel formulations for exclusive b2b licensing.

This dual approach enables pharmaceutical companies to leverage Shilpa's extensive expertise in oncology without the direct risks and lengthy timelines associated with development.

The CDMO currently has multiple assets in its pipeline and three late-stage products available for licencing at Drug, Chemical & Associated Technologies Association (DCAT). Through this model, pharma companies can expedite their market entry by licensing fully developed products while still benefiting from Shilpa's robust development and manufacturing capabilities.

Commenting on the business realignment and hybrid model, Vishnukant C. Bhutada, Managing Director of Shilpa Medicare, commented, "Our goal is to offer pharmaceutical and biotech customers multiple flexible pathways to bring commercial products to market. On the one hand, they can leverage our development teams, cutting-edge technologies, and world-class facilities in a traditional CDMO partnership – with both our GLP-1 and biologics services in high demand at DCAT. On the other, we have a pipeline of fully developed products that are available for exclusive licensing, eliminating development risks for our partners. However, we remain strictly a b2b-only company, ensuring we never compete with our clients."

Shilpa Medicare has seen rapid growth in recent years, achieving a turnover of over \$150 million. The company is well-positioned to capitalise on the increasing trend of pharmaceutical outsourcing to India, offering an extensive infrastructure with five state-of-the-art R&D centres and six manufacturing facilities.